Breast cancer drug Phesgo will be reimb next month
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.07.22 05:45:44
가나다라
0
Perjeta+Herceptin combination… fixed-dose subcutaneous injection offers improved convenience
Had been in a tug of war with HIRA due to its big financial impact…concludes drug pricing negotiations 11 months after passing CDDC review
The drug was approved in September 2021, and in August last year, the Health Insurance Review and Assessment Service's Cancer Disease Review Committee (CDDC) set the standards for its reimbursement, but no news on its progress has been heard of since.
According to industry sources on the 19th, Roche has completed negotiations with the National Health Insurance Service on supply and quality control obligations, and Phesgo will be listed on the payroll next month after being reported to the Health Insurance Policy Review Committee.
The drug is a fixed-dose
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)